Systemic Clinical Trials

420 recruitingLast updated: May 13, 2026

There are 420 actively recruiting systemic clinical trials across 72 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include New York, New York, United States, Paris, France, Houston, Texas, United States. Updated daily from ClinicalTrials.gov.


Systemic Trials at a Glance

420 actively recruiting trials for systemic are listed on ClinicalTrialsFinder across 6 cities in 72 countries. The largest study group is Phase 1 with 119 trials, with the heaviest enrollment activity in New York, Paris, and Houston. Lead sponsors running systemic studies include AstraZeneca, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, and The Children's Hospital of Zhejiang University School of Medicine.

Treatments under study

About Systemic Clinical Trials

Looking for clinical trials for Systemic? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Systemic trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Systemic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 420 trials

Recruiting
Phase 1Phase 2

A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE

Lupus Erythematosus, Systemic
AstraZeneca150 enrolled18 locationsNCT06897930
Recruiting
Phase 4

Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users

Systemic Lupus Erythematosus
AstraZeneca16 enrolled1 locationNCT06594068
Recruiting

NIS to Examine Disease Activity in SLE Patients Treated With Subcutaneous Anifrolumab in Routine Care

Lupus Erythematosus, Systemic
AstraZeneca125 enrolled16 locationsNCT07424261
Recruiting
Phase 1

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD)

dry eye syndromeSystemic Lupus Erythematosus
AbbVie36 enrolled6 locationsNCT06977724
Recruiting
Phase 2

A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Guangdong Hengrui Pharmaceutical Co., Ltd248 enrolled2 locationsNCT07299422
Recruiting
Phase 1

A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus
Hoffmann-La Roche70 enrolled24 locationsNCT05835986
Recruiting
Phase 1Phase 2

Controlling Hyperactive Immunity With Long-lived Lymphocytes

Rheumatoid Arthritis (RA)Autoimmune Rheumatologic DiseaseDiffuse Cutaneous Systemic Sclerosis+1 more
Quell Therapeutics Limited16 enrolled6 locationsNCT07473154
Recruiting
Phase 2

A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)

Lupus Erythematosus, SystemicLupus Nephritis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company89 enrolled93 locationsNCT07015983
Recruiting
Phase 3

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic
Janssen Research & Development, LLC600 enrolled69 locationsNCT07438496
Recruiting
Phase 1Phase 2

Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients

Systemic Light Chain Amyloidosis
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.70 enrolled27 locationsNCT07266116
Recruiting
Phase 1

A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases

HealthyIdiopathic Inflammatory MyopathiesSystemic Sclerosis+1 more
Xencor, Inc.60 enrolled1 locationNCT07284797
Recruiting
Phase 3

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease

Systemic Lupus Erythematosus (SLE)Cutaneous Lupus Erythematosus (CLE)
EMD Serono Research & Development Institute, Inc.202 enrolled5 locationsNCT07332481
Recruiting
Phase 2

A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases

Systemic Lupus ErythematosusActive Refractory Rheumatoid Arthritis
Amgen220 enrolled54 locationsNCT06570798
Recruiting
Not Applicable

Brief Pain Exposure Therapy (BPET) For Nociplastic Pain

Chronic Low Back Pain (CLBP)FibromyalgiaLupus Erythematosus, Systemic+1 more
University of Michigan125 enrolled1 locationNCT06208514
Recruiting
Not Applicable

Improving Health Outcomes With Kefir

Cardiovascular DiseasesDiabetes Mellitus, Type 2Systemic Inflammatory Response
University of Alberta156 enrolled1 locationNCT06695221
Recruiting

Prospective User Study and Multicenter Validation of Multimodal Medical Imaging Large Models

Artificial Intelligence (AI)Diagnostic ImagingCommon Systemic Diseases
The Third Affiliated Hospital of Southern Medical University1,000 enrolled1 locationNCT07555002
Recruiting
Phase 3

An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants

Systemic Lupus Erythematosus
AstraZeneca100 enrolled98 locationsNCT05835310
Recruiting
Not Applicable

African Americans (AA) Communities Speak

Health Knowledge, Attitudes, PracticeHealthy AgingSocial Responsibility+2 more
University of Alabama at Birmingham60 enrolled2 locationsNCT05908487
Recruiting
Phase 2

Intralesional Injection of STS in Treatment of Calcinosis

DermatomyositisSystemic Sclerosis (SSc)Mixed Connective Tissue Disease (MCTD)+1 more
Robyn T. Domsic, MD, MPH20 enrolled1 locationNCT06672822
Recruiting
Not Applicable

Fatigue in Lupus Intervention Programmes (FLIP)

Systemic Lupus Erythematosus
University of Edinburgh90 enrolled1 locationNCT06308770